RT Journal Article SR Electronic T1 Candidate drug replacements for quinacrine in cutaneous lupus erythematosus JF Lupus Science & Medicine JO Lupus Sci Med FD Lupus Foundation of America SP e000430 DO 10.1136/lupus-2020-000430 VO 7 IS 1 A1 Daisy Yan A1 Robert Borucki A1 Richard D Sontheimer A1 Victoria P Werth YR 2020 UL http://lupus.bmj.com/content/7/1/e000430.abstract AB Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy.